We are committed to participating in European Research Programmes and are open to collaborations with large multinational and EU research consortia. In addition to our dedication to quality, our range of services and our focus on biospecimen research, make us an the ideal biobanking and biomarker validation partner for consortium research projects from the European Research Programmes such as the 7th Framework Programme (FP7), the new Horizon 2020 programme and the Innovative Medicines Initiative (IMI).

Added value through a comprehensive range of services

Through our biobanking and biomarker validation expertise we can contribute the following activities to research consortia:

  • Ÿ Biospecimen collection, sample processing and storage
  • Ÿ Biorepository logistics and IT infrastructure
  • Ÿ Sample testing and assay validation, biospecimen testing and validation
  • Ÿ Biospecimen quality control
  • Ÿ Well-annotated (clinical, pre-analytical, pathological, molecular annotations) retrospective and prospective samples
  • Ÿ Tools to standardise pre-analytical parameters (sample collection and validation)
  • Ÿ Production of reference materials according to ISO Guide 34 standards
  • Ÿ Proficiency testing services on sample processing, sample analysis, according to ISO17043 standards
  • Ÿ Validation of biomarkers and establishment of corresponding analytical procedures according to ISO17025 standards
  • Ÿ Standard operating procedures (SOPs)

An experienced biobanking and validation partner

We are currently participating in the following EU consortia and projects:

  • ŸLITMUS, an Innovative Medicines Initiative (IMI) project for the development and validation of biomarkers for non-alcoholic fatty liver disease. Read more >
  • SPIDIA4P, a Horizon2020 project on standardisation of pre-analytics. Read more >
  • CANCER-ID, an Innovative Medicines Initiative (IMI) project on the validation of blodd-based biomarkers for cancer. Read more >
  •  3DPD (Advanced modelling of Parkinson’s disease with threedimensional human midbrain organoids)  project of the European Union Joint Programme for Neurodegenerative Disease (JPND) Research Read more >
  • Ÿ European Union-supported MINDACT study (Microarray In Node negative Disease may Avoid ChemoTherapy). Read more >
  • Ÿ BIOMARKAPD project of the European Union Joint Programme for Neurodegenerative Disease (JPND) Research. Read more >
  • Ÿ European Commission FP7 Framework Programme: STORE (for Sustaining access to Tissue and data from Radiobiological Experiments). Read more >

Interested in collaborating with us and finding out more about how we can add value to your consortium?

You may be interested in:

  • The value of a central biobank for EU consortia

    When you bring together people that tackle a problem from different angles, you are more likely to […]

  • IBBL participates in another international consortium on Parkinson’s disease

    In a new international research project, funded by the EU Joint Programme – Neurodegenerative Disease Research (JPND) […]


    As an ISO 9001 (general quality management) certified organisation compliant with the principles of ISO 17025 accreditation […]